Associate Professor Andrew Jabbour, of the Victor Chang Cardiac Research Institute, said the new development will lead to major improvements in care for many thousands of heart transplant patients worldwide. "It’s essential that we can monitor these patients closely and with a high degree of accuracy; now we have a new tool that can do that without the need for a highly invasive procedure," said A/Prof Jabbour who is also a Consultant Cardiologist at St Vincent’s Hospital, Sydney.
"This new virtual biopsy takes less time, is non-invasive, more cost-effective, uses no radiation or contrast agents, and most importantly patients much prefer it."
Most clinicians around the world currently test for rejection by performing a biopsy which helps determine the level and suitability of immunosuppressive treatments needed to treat and prevent further rejection.
This invasive procedure involves a tube being placed in the jugular vein to allow surgeons to insert a biopsy tool into the heart to remove multiple samples of heart tissue. As well as being uncomfortable, it can also lead to rare but serious complications if the heart is perforated, or a valve is damaged. Patients usually undergo a biopsy around 12 times in the first year after transplantation.
The new MRI technique has been proven to be accurate in detecting rejection and works by analysing heart oedema levels which the team demonstrated are closely associated with inflammation of the heart.
- Forty heart transplant patients from St Vincent’s Hospital, Sydney were randomised into receiving either a traditional biopsy or the new MRI technique.
- Results published in the journal Circulation revealed the new test was just as effective as detecting rejection.
- Secondary findings of the study revealed that despite similarities in immunosuppression requirements, kidney function and mortality rates, there was a reduction in hospitalization and infection rates for those who underwent the MRI procedure vs a biopsy. Also, just six percent of patients having the new MRI technique needed a biopsy for clarification reasons. These secondary findings are earmarked to be reconfirmed in planned larger multi-centre studies.
Fellow author and cardiologist Dr Chris Anthony, who helped conduct the study, said: "The technique is now frequently used at St Vincent’s Hospital in Sydney, and I anticipate that more clinics across the world will adopt this novel technology."
The team at the Institute and St Vincent’s is now planning a larger multi-centre trial to broaden the applicability of the findings and incorporate paediatric transplant recipients.
They are also developing new genetic testing to be used alongside the MRI which it is hoped will detect signs of rejection through identifying genetic signals of donor-specific inflammation in the bloodstream. The new technique will also be adapted to detect heart inflammation in the wider population, not just transplant recipients.
MEDICA-tradefair.com; Source: Victor Chang Cardiac Research Institute